Target's General Information
Target ID T47101
Target Name Fibroblast growth factor receptor 1 (FGFR1)
Synonyms c-fgr; bFGF-R-1; bFGF-R; N-sam; HBGFR; Fms-like tyrosine kinase 2; FLT2; FLT-2; FLG; FGFR-1; FGFBR; CEK; CD331 antigen; CD331; Basic fibroblast growth factor receptor 1; BFGFR
Target Type Successful
Gene Name FGFR1
Biochemical Class Kinase
UniProt ID FGFR1_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Atopic dermatitis
Example drug AM-001 Phase 2 [1], [2], [3]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.12
Z-score: -0.72
P-value: 1.06E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Ovarian cancer
Example drug Nintedanib Phase 2 [2], [3], [4], [5], [6]
Tissue Ovarian tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.74
Z-score: -1.73
P-value: 3.31E-03
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 3.09E-04
Z-score: 1.35E-03
P-value: 1.25E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Uterine cancer
Example drug FP-1039 Phase 2 [7], [2], [3]
Tissue Endometrium tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.2
Z-score: -0.38
P-value: 1.04E-02
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: -0.5
Z-score: -2.14
P-value: 1.80E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Retinoblastoma tumor
Example drug PD-0183812 Terminated [8], [2], [3]
Tissue Uvea
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.58
Z-score: -2.4
P-value: 3.33E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Alzheimer's disease
Example drug MK-2461 Phase 1/2 [9], [2], [3]
Tissue Entorhinal cortex
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.03
Z-score: -0.15
P-value: 4.79E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Acute myelocytic leukemia
Example drug KW-2449 Phase 1 [10], [11], [2], [3]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 1.24E-03
Z-score: 4.64E-03
P-value: 5.16E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Liver cancer
Tissue Liver tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.12
Z-score: -0.59
P-value: 1.18E-03
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: -0.08
Z-score: -0.28
P-value: 3.61E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Parkinson's disease
Tissue Substantia nigra tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.02
Z-score: -0.16
P-value: 7.85E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Renal cancer
Tissue Kidney
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.07
Z-score: 0.28
P-value: 2.92E-01
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 0.09
Z-score: 0.22
P-value: 1.99E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 ClinicalTrials.gov (NCT01938599) Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis. U.S. National Institutes of Health.
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936).
REF 5 ClinicalTrials.gov (NCT01979952) Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
REF 6 ClinicalTrials.gov (NCT02231164) LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research. U.S. National Institutes of Health.
REF 7 ClinicalTrials.gov (NCT01244438) Study of FP-1039 in Subjects With Endometrial Cancers. U.S. National Institutes of Health.
REF 8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014130)
REF 9 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
REF 10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5691).
REF 11 KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.